Copanlisib dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Copanlisib dihydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
73
Registered trials
96
Result records
15
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Copanlisib dihydrochloride can convert its Small molecule drug profile and PI3Kα x PI3Kδ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Copanlisib dihydrochloride (query alias: copanlisib) |
|---|---|
| Modality / target | Small molecule drug; PI3Kα x PI3Kδ; PI3Kα inhibitors, PI3Kδ inhibitors |
| Highest global status | Approved |
| Originator | Bayer AG |
| Active developers | The University of Texas MD Anderson Cancer Center, National Cancer Institute, Bayer AG |
The MCP disease footprint includes Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone B-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06400238 | Phase 2 | Active, not recruiting | 35 | Objective Response Rate (ORR) |
| NCT06360588 | Phase 2 | Active, not recruiting | 22 | Objective Response Rate (ORR) |
| NCT06218667 | Phase 1/2 | Withdrawn | Not disclosed | phase Ib determine the recommended phase 2 dose (RP2D) of copanlisib in combination with degarelix |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Phase 2; n=33; evaluation: not stated. Reported fields: Proportion of Participants Who Achieve Positron Emission Tomography (PET) - Negative Complete Response = 0.48 proportion of participants (95% Confidence Interval, 0.31 - 0.66); -; -
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Phase 1; n=39; evaluation: not stated. Reported fields: DLT = 0 Participants ; DLT = 0 Participants ; DLT = 0 Participants
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer
Phase 1/2; n=24; evaluation: not stated. Reported fields: -; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Copanlisib dihydrochloride addresses Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone B-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 15 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PI3Kα x PI3Kδ records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-10 | Laekna enter an Exclusive License Agreement with Vasque Bio for LAE118 (a novel PI3Kα pan-mutant selective inhibitor) in Ex-China Region | Phase 1 | US$10.0M upfront; US$517.0M milestones |
| 2026-03-20 | Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program | Phase 1/2 | US$2,000.0M upfront; US$1,000.0M milestones; US$3,000.0M stated total |
| 2025-10-16 | Taiho Pharma Enters Into Exclusive License Agreement with Haihe Biopharma for PI3Kα Inhibitor Risovalisib (CYH33) | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Drug combination comprising Anti-CD37 antibody maytansine conjugate and BCL2 inhibitor or PI3k inhibitor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
